Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis

Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. Results: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both atendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. Conclusion: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.

Original languageEnglish
Pages (from-to)119-128
Number of pages10
JournalYonsei Medical Journal
Volume49
Issue number1
DOIs
Publication statusPublished - 2008 Feb

Fingerprint

Alendronate
Bone Remodeling
Lipid Metabolism
Bone Density
Osteoporosis
Serum
LDL Cholesterol
Alkaline Phosphatase
Triglycerides
Raloxifene Hydrochloride
HDL Cholesterol
Spine
Cholesterol

Keywords

  • Alendronate
  • Lipid metabolism
  • Osteoporosis
  • Postmenopausal women
  • Raloxifene

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. / Iwamoto, Jun; Sato, Yoshihiro; Uzawa, Mitsuyoshi; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Yonsei Medical Journal, Vol. 49, No. 1, 02.2008, p. 119-128.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Sato, Yoshihiro ; Uzawa, Mitsuyoshi ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. In: Yonsei Medical Journal. 2008 ; Vol. 49, No. 1. pp. 119-128.
@article{ba8945805fe547ffba5086fa21c17f04,
title = "Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis",
abstract = "Purpose: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. Results: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both atendronate and raloxifene increased lumbar BMD (+8.0{\%} and +2.4{\%} at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9{\%} and -7.7{\%} at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. Conclusion: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.",
keywords = "Alendronate, Lipid metabolism, Osteoporosis, Postmenopausal women, Raloxifene",
author = "Jun Iwamoto and Yoshihiro Sato and Mitsuyoshi Uzawa and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2008",
month = "2",
doi = "10.3349/ymj.2008.49.1.119",
language = "English",
volume = "49",
pages = "119--128",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

TY - JOUR

T1 - Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Uzawa, Mitsuyoshi

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2008/2

Y1 - 2008/2

N2 - Purpose: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. Results: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both atendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. Conclusion: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.

AB - Purpose: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. Results: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both atendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. Conclusion: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.

KW - Alendronate

KW - Lipid metabolism

KW - Osteoporosis

KW - Postmenopausal women

KW - Raloxifene

UR - http://www.scopus.com/inward/record.url?scp=41949117901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949117901&partnerID=8YFLogxK

U2 - 10.3349/ymj.2008.49.1.119

DO - 10.3349/ymj.2008.49.1.119

M3 - Article

C2 - 18306478

AN - SCOPUS:41949117901

VL - 49

SP - 119

EP - 128

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -